Fibrocell Shares Plummet Following Disappointing Clinical Study

By

fibrocell
Exton’s Fibrocell saw its share price drop by over a third on Wednesday after it announced disappointing clinical trial results for azficel-T.

Exton based Fibrocell Science saw over a third of its share value disappear on Wednesday, after it announced disappointing results from the second-stage clinical trial on its experimental treatment for vocal cord scarring, writes John George for Philadelphia Business Journal.

The treatment called azficel-T, was supposed to help with vocal cord scarring resulting in chronic or severe dysphonia. However, during the second stage study which was a double blind, placebo controlled trial to test the safety and effectiveness of azficel-T injections, the primary endpoints were not met versus the placebo after four months of treatment.

David Pernock, Chairman and CEO of Fibrocell, commented that “we are disappointed that azficel-T did not demonstrate the anticipated benefits for patients in this phase-II clinical trial” but he noted that “we will continue to assess the data to gain greater insight into the study’s outcome and follow the patients through the final 12 month endpoint for the trial.”

Despite this setback, Fibrocell is already moving forward with development of another new drug candidate, FCVX-007. This is a potential treatment for recessive dystrophic epidermolysis bullosa, an incurable and often fatal form of skin blistering caused by a lack of collagen protein in a person’s skin.

The company also has hopes for earlier stage programs in preclinical development such as its gene therapy for the autoimmune disease linear scleroderma.

Read more at Philadelphia Business Journal here and check out previous VISTA Today coverage of Fibrocell here.

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Advertisement
Creative Capital logo